<DOC>
	<DOCNO>NCT01151722</DOCNO>
	<brief_summary>Postoperative vitreous hemorrhage common complication vitrectomy proliferative diabetic retinopathy . There effort low incidence postoperative vitreous hemorrhage preoperative bevacizumab injection . Bevacizumab ( Avastin ) potent inhibitor angiogenesis show decrease retinal iris neovascularization proliferative diabetic retinopathy . Recently report show preoperative bevacizumab injection could reduce intraoperative bleeding abnormal vessel could make surgery easy successful . Our hypothesis intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage inhibit vessel formation surgery . We start prospective randomize comparative study determine effect pre intra-operative bevacizumab injection postoperative vitreous hemorrhage diabetic vitrectomy comparison vitrectomy without adjuvant drug .</brief_summary>
	<brief_title>Adjuvant Intravitreal Bevacizumab Pars Plana Vitrectomy Diabetic Vitreous Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient undergo first vitrectomy vitreous hemorrhage secondary proliferative diabetic retinopathy followup period le 3 month first vitrectomy abnormal blood coagulation uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>